Related references
Note: Only part of the references are listed.2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists
Yixin Ren et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2022)
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Wenying Yang et al.
NATURE MEDICINE (2022)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naive Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial
Dongyang Liu et al.
ECLINICALMEDICINE (2021)
Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
Konstantinos A. Toulis et al.
DRUGS (2020)
Synthesis and Pharmacological Activity of 3-Phenoxybenzoic Acid Derivatives
A. A. Spasov et al.
PHARMACEUTICAL CHEMISTRY JOURNAL (2020)
Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025
Xiling Lin et al.
SCIENTIFIC REPORTS (2020)
The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans
Franz M. Matschinsky et al.
FRONTIERS IN PHYSIOLOGY (2019)
Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
Mikhail S. Dzyurkevich et al.
SCIENTIFIC REPORTS (2017)
Effects of Piragliatin, a Glucokinase Activator, on Fasting and Postprandial Plasma Glucose in Patients With Type 2 Diabetes Mellitus
Jianguo Zhi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development
Puneet Gaitonde et al.
CLINICAL PHARMACOKINETICS (2016)
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study
William S. Denney et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk
Kris A. Borzilleri et al.
MEDCHEMCOMM (2014)
Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables
Li-Nong Ji et al.
BMC PUBLIC HEALTH (2013)
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
A. Kiyosue et al.
DIABETES OBESITY & METABOLISM (2013)
Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics
Nicolai M. Doliba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats
Wei Gao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus
Jeffrey A. Pfefferkorn et al.
MEDCHEMCOMM (2011)
Associations Between Features of Glucose Exposure and A1C The A1C-Derived Average Glucose (ADAG) Study
Rikke Borg et al.
DIABETES (2010)
Handling Data Below the Limit of Quantification in Mixed Effect Models
Martin Bergstrand et al.
AAPS JOURNAL (2009)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Share Paper
